Find therapies in clinical trials near you

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

DNAJB1-PRKACA trifluoracetate peptide vaccine and atezolizumab in patients with fibrolamellar hepatocellular carcinoma and other DNAJB1-PRKACA fusion tumors

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

A study of YL201 and atezolizumab for patients with advanced solid tumors

A study of YL201 and atezolizumab for patients with advanced solid tumors

Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas